421 related articles for article (PubMed ID: 22925614)
21. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
22. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
Milionis H
Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
[TBL] [Abstract][Full Text] [Related]
23. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
24. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
25. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Raposo HF; Patrício PR; Simões MC; Oliveira HC
J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
[TBL] [Abstract][Full Text] [Related]
26. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X
Clin Investig Arterioscler; 2018; 30(4):188-192. PubMed ID: 29789212
[TBL] [Abstract][Full Text] [Related]
27. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
28. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
29. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
30. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
Vincenzi B; Borba CP; Gray DA; Copeland PM; Wang X; Fan X; Aragam GG; Henderson DC
Ann Clin Psychiatry; 2013 May; 25(2):141-8. PubMed ID: 23638445
[TBL] [Abstract][Full Text] [Related]
31. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2004 Dec; 3():10. PubMed ID: 15574199
[TBL] [Abstract][Full Text] [Related]
32. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
33. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
34. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
Loomba RS; Arora R
Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
36. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
Francik R; Kryczyk J; Francik S
Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
[TBL] [Abstract][Full Text] [Related]
37. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
[TBL] [Abstract][Full Text] [Related]
38. Fibrates, dyslipoproteinaemia and cardiovascular disease.
Watts GF; Dimmitt SB
Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
[TBL] [Abstract][Full Text] [Related]
39. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
